Department of Internal Medicine, Beaumont Hospital, Royal Oak, MI, United States of America.
Department of Cardiovascular Medicine, Mayo Clinic School of Medicine, Rochester, MN, United States of America.
Cardiovasc Revasc Med. 2023 Jun;51:67-74. doi: 10.1016/j.carrev.2023.01.019. Epub 2023 Jan 30.
In-stent restenosis (ISR) has been a major limitation in interventional cardiology and constitutes nearly 10 % of all percutaneous coronary interventions in the United States. Drug-eluting stent (DES) restenosis proves particularly difficult to manage and poses a high risk of recurrence and repeat intervention. Intra-coronary brachytherapy (IBT) has been traditionally viewed as a potential treatment modality for ISR. However, its use was hindered by procedural complexity, cost, and the advent of newer-generation DES. Recent data suggests promising results regarding IBT for the treatment of resistant DES-ISR. This review addresses the mechanism of action of IBT, procedural details, and associated risks and complications of its use. It will also highlight the available clinical evidence supporting the use of IBT and the future directions of its utilization in the treatment of ISR.
支架内再狭窄(ISR)一直是介入心脏病学的主要限制因素,占美国所有经皮冠状动脉介入治疗的近 10%。药物洗脱支架(DES)再狭窄尤其难以治疗,并且存在高复发和再次介入的风险。冠状动脉内放射治疗(IBT)一直被视为 ISR 的一种潜在治疗方法。然而,由于操作复杂、成本高以及新一代 DES 的出现,其应用受到了阻碍。最近的数据表明,IBT 治疗耐药性 DES-ISR 具有有前景的结果。本综述介绍了 IBT 的作用机制、操作细节以及其使用的相关风险和并发症。它还将重点介绍支持使用 IBT 的现有临床证据以及未来在治疗 ISR 中的应用方向。